<DOC>
	<DOCNO>NCT02874807</DOCNO>
	<brief_summary>Syndrome inappropriate antidiuresis ( SIADH ) characterize imbalance antidiuretic vasopressin ( AVP ) secretion . The impaired AVP regulation lead water retention secondary natriuresis common cause hyponatremia . The therapeutic option , aside treat underlie disease , depend upon onset severity symptom involve usually fluid restriction hypertonic saline infusion . Alternative therapeutic option loop diuretic , administration oral urea vasopressin receptor antagonist ( vaptans ) . Despite option , considerable number patient sufficiently respond , make additional therapy necessary . Empagliflozin ( Jardiance ) ® sodium glucose co-transporter 2 ( SGLT2 ) -inhibitor , new treatment option develop patient diabetes mellitus type 2 . The SGLT2 express proximal tubule reabsorb approximately 90 percent filter glucose . The inhibition SGLT2 result renal excretion glucose subsequent osmotic diuresis . This mechanism could result therapeutic effect patient hypotonic hyponatremia SIADH . The aim study evaluate whether empagliflozin ( Jardiance ) ® effect serum sodium level patient SIADH .</brief_summary>
	<brief_title>Effects SGLT2-inhibitor Empagliflozin Patients With SIADH - SAND Study</brief_title>
	<detailed_description />
	<mesh_term>Inappropriate ADH Syndrome</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Hyponatremia &lt; 130mmol/l due SIADH Treatment SIADH &gt; 48h study start severe illness ICUAdmission Treatment 3 % sodium Chloride ( NaCl ) solution uncontrolled hypothyroidism uncontrolled adrenal insufficiency severe renal impairment ( GFR &lt; 30ml/min ) , end stage renal disease severe hepatic impairment ( ChildPugh class C ) systolic blood pressure &lt; 90mmHg Diabetes mellitus type 1 acute myocardial infarction chronic venous insufficiency ( CVI ) Treatment SGLT2 Inhibitor , Lithium Chloride Urea recurrent urinary/genital tract infection contraindication lower blood pressure severe immunosuppression pregnancy breastfeed palliative care</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hyponatremia</keyword>
	<keyword>SGLT2 inhibitor</keyword>
</DOC>